Unlock instant, AI-driven research and patent intelligence for your innovation.

Salt forms of bempedoic acid and methods for using the same

A technology of calcium salt and potassium salt, applied in the field of pharmaceutical composition or preparation

Pending Publication Date: 2021-03-02
ЕСПЕРІОН ТЕРАПЕУТІКС ІНК
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] The development of reliable, cost-effective and efficient manufacturing methods to prepare pharmaceutically active compounds in desirable yields and purity remains a significant challenge

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Salt forms of bempedoic acid and methods for using the same
  • Salt forms of bempedoic acid and methods for using the same
  • Salt forms of bempedoic acid and methods for using the same

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0557] Embodiment 1: the preparation process of the pharmaceutical material comprising the compound of formula (V) in a purified amount

[0558] In this example, the synthesis of purified bempedelic acid refers to figure 1 .

[0559] Step 1 - Preparation of compound of formula (I)

[0560] Lithium diisopropylamide (LDA) preparation

[0561] Diisopropylamine (317±3 kg, 1.1 equiv) and tetrahydrofuran (THF, 2,102±105 L) were added to the reaction vessel, and the mixture was then cooled to ≤-10°C. n-Butyllithium (n-BuLi, 757±8 kg, 1.2 equivalents) was then added within ≥1 hour while maintaining the temperature ≤-10°C. The feed line was flushed with THF. Addition is highly exothermic. Finally, the batch was cooled back to <-10°C while stirring.

[0562] Alkylation reaction

[0563] Ethyl isobutyrate (317 ± 3 kg, 1.1 equivalents) was added to the reactor at ≤ -10 °C for ≥ 1 hour ( figure 1 ). The batch was stirred while maintaining the temperature < -10°C. 1-Bromo-5-chlo...

Embodiment 2

[0663] Example 2: Alternative Preparation Process for the Preparation of Pharmaceutical Materials Comprising Purified Amounts of Compounds of Formula (V)

[0664] Step 1 - Preparation of compound of formula (I)

[0665] Lithium diisopropylamide (LDA) preparation

[0666] About 321 kg of diisopropylamine and about 1870 L of tetrahydrofuran (THF) were added to the reaction vessel, and the mixture was then cooled to -18°C to -5°C. About 794 kg of n-butyllithium (n-BuLi, solution in heptane) was slowly added while maintaining the temperature at -18°C to -5°C. The batch was maintained at -18°C to -5°C with stirring.

[0667] Alkylation reaction

[0668] Approximately 317 kg of ethyl isobutyrate was added to the reactor containing LDA over a target time of ≥ 1 hour, and the temperature was controlled at -18°C to -5°C. The line is then flushed with about 100 L of THF. The batch was stirred while maintaining the temperature at -18°C to -5°C. Approximately 460 kg of 1-bromo-5-c...

Embodiment 3

[0729] Embodiment 3: the analytical method of the purity of measuring formula (V) compound

[0730] Determination of impurities

[0731] The impurity content of the compound of formula (V) in purified form was determined using a high performance liquid chromatograph equipped with a gradient function, a thermostatic column compartment and a detector with aerosol detection (CAD).

[0732] The impurity content of the compound of formula (V) in purified form was determined to be 0.05-0.50% w / w.

[0733] Column: Waters XBridge BEH C18 (4.6mm inner diameter x 150mm, 2.5μm)

[0734] Mobile phase: A: 0.05% formic acid (HCOOH) / water (H 2 O)

[0735] Mobile phase: B: 0.05% HCOOH / acetonitrile (ACN)

[0736] Sample temperature: ambient

[0737] Column temperature: 40°C

[0738] Gradient (time: A:B): (0min:90:10; 8.5min., 56:44; 20min., 45:55; 32min., 5:95; 36min., 5:95).

[0739] Flow rate: 1.2mL / min

[0740] Retention time: ~15.2min (bempedic acid in purified form)

[0741] ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides crystalline salt and cocrystal forms of bempedoic acid. Also provided are compositions and pharmaceutical materials including a crystalline salt or co-crystal form of bempedoicacid as well as methods of treating various diseases and conditions using the compositions and pharmaceutical materials.

Description

[0001] cross reference [0002] This application claims the benefit of and priority to U.S. Patent Application No. 62 / 864,873, filed June 21, 2019, the entire contents of which are incorporated herein by reference. Background technique [0003] The development of reliable, cost-effective and efficient manufacturing methods to prepare pharmaceutically active compounds in desirable yield and purity remains a significant challenge. Bempedoic acid (8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid) is a drug developed for the treatment of various diseases including liver disease and cardiovascular disease. compound. Therefore, there is a need for a method of synthesizing bempedic acid (8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid) such that the product has the purity and impurities required by regulatory agencies to produce a commercially viable drug product characteristic. [0004] In addition, crystalline salts and co-crystal forms of bempedelic acid are also ideal...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07C59/245C07C53/126A61K31/20A61K31/205A61P3/06A61P9/00C07C229/12C07C211/05C07D213/81C07C229/26C07D295/027C07C215/10C07K5/075
CPCA61P3/06A61K31/20C07C315/00C07C51/09C07C67/307C07C67/313C07C67/31C07C317/36C07C59/245C07C69/62C07C69/738C07C69/732C07B2200/13C07C315/04C07C51/04C07C51/42C07C59/285C07C51/47C07C51/43A61K31/194A61K31/191
Inventor R.科普M.阿布德尔纳瑟C.M.西马鲁斯蒂C.刘
Owner ЕСПЕРІОН ТЕРАПЕУТІКС ІНК